Although immunotherapy can unleash CD8+ T cells and specific mutation-associated neoantigens, some tumor microenvironment factors (such as hypoxia and toxic metabolites) inhibit T cell activation (37, 38). This evidence concerns the gene CD8A and neoplasm.